TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bronchodilator utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dental plaque accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With First CEC Confirmed Primary Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: itch-associated local biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Patients not progressing to operation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Caregivers Retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline low back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICDAS Severity Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial Artery Flow-Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite incidence of stroke/ non-CNS SE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Final mode of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: satisfaction of patients and endoscopist
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral-cecal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline intestinal microbiota composition at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline liver health biomarkers at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from cognitive function at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regression of plus disease or active neovessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Complete retinal vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change from baseline in chair stand test (repetitions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in session attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent of patients with any adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with HIV-1 RNA levels of less than 400 copies per milliliter after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in CD4 cell count and overall efficacy evaluation by investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of a new thrombotic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Insulin Biosynthesis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Re-transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduced number of prolonged sitting bouts (>30 min)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in symptoms of the primary illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood loss on the post-operative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in LDL Cholesterol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Box-Block Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: diagnosis accuracy for significant fibrosis and cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in e-coupon redemption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in SRH service uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Interleukin 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of risk-reducing salpingo-oophorectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement of responses to NIV reading grid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Tanner Stage V at or Before Age 16 (Females) or 17 (Males)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Notably Low and Notably High Height and Body Mass Index (BMI) Standard Deviation Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endocrine Laboratory Values LH and FSH in Male Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of a Significant Threshold Shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of apicomarginal defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants alive one year after randomisation
Endpoint domain: Mortality/survival
Primary endpoint: Remission of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: analgesia need at the post-operative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative rescue tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Hematopoietic Cytopenias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infant HIV Infection Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glycated Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Montgomery-Ǻsberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Achieved SVR12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of brain AD pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Allograft Survival
Endpoint domain: Mortality/survival
Primary endpoint: plasma sVCAM-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Disease Activity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Articular cartilage morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Numeric Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change from Baseline in Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient satisfaction of the abdomen
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of cone beam CT for image guidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of DNA and RNA obtained from tumor biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to perform Genome-Wide Sequencing (GWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with clearance of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with tumor recurrence or metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Time of tumor recurrence or metastasis
Endpoint domain: Mortality/survival
Primary endpoint: gestation weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0, t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: The Holmes and Rahe stress scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity/resistance patterns of Immunosuppressant drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vaginal Maturation Index (VMI) absolute change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration (AUCt) of lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Catheter-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in iHOT-33 Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for additional uterotonics intraoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall and PARDS-specific mortality rates for children admitted for severe pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: AUC of Candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of Candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Exercise Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Incidental Face Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Contextual Assessment of Social Skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Social Responsiveness Scale - Self (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Social Responsiveness Scale - Parent (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Firmicutes:Bacteroides ratio (F:B Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLI-specific health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumor proliferation (Ki67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proliferation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage change in total hip bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with clinical improvement in EDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of Lu-177 DOTA-TATE in treating neuroendocrine tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FHL Severity at Maximum Eyebrow Elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in severity of OCD symptoms (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in severity of OCD symptoms (A-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in severity of OCD symptoms (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in suicidality (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fear of Self-Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Self-Hatred
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Individual Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complicated skin and skin structure infections (cSSSI) resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gram-positive catheter-related bloodstream infections resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Moderate or Severe Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: short term outcomes after repair for severe cardiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Take-home Baby Rate
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Hyperglycaemia (>126 mg/dL) in Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Episodes of Hyperglycaemia (>126 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of recurrence after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants without any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Psychosocial parameters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relational parameters
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ECT efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of passes required to establish a diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostatic Tumor Vessel Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of detection of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sample collection at Day 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood sample collection at Day 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood sample collection at onset of CvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in IL17A Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastric Emptying Half Time Measured by Scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric Emptying Half Time Measured by 13C Spirulina Gastric Emptying Breath Test (GEBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood phosphate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma lanthanum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Image Quality Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Timed 25-Foot Walk (T25FW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Follow-up compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC and Cmax of darapladib and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar fat pad thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTG values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emotional Change of Nursing Manpower
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of poor and positive parenting on the Parenting Scale (PS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of poor and positive parenting on the Parent Behaviour Inventory (PBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of poor and positive parenting on the Parenting Young Children Scale (PARYC) - Setting Limits subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of child problem behaviour on the Eyberg Child Behaviour Inventory (ECBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Family Needs Questionnaire (FNQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of transient ischemic attack
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carotid intima media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to 1st flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to 1st diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serologic Response (4 fold HI titer rise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and Severity of Cytokine-release Syndrome (CRS)
Endpoint domain: Adverse events/effects
Primary endpoint: cervical JOA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of the variations of expression of HIF-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve [AUC(0-inf)] of selexipag and ACT-333679
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of selexipag and ACT-333679
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient global perceived effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Biopsy-Proven Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of retrained urethral catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of participants with complete molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p16INK4a expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of correct squats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetics of tacrolimus or cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes